Cullgen Completes Phase 1 Enrollment for Novel Non-Opioid Pain Therapy CG001419
Key Insights
Cullgen (search) has completed enrollment in its Phase 1 clinical trial for CG001419, a potential first-in-class oral pan-TRK (search) protein degrader designed to treat pain without opioid addiction risks.
The randomized, placebo-controlled trial in healthy volunteers evaluates the safety, tolerability and pharmacokinetic characteristics of this novel non-opioid, non-NSAID analgesic therapy.
The company plans to file an IND with the FDA and initiate Phase 2 trials for CG001419 in pain management by early 2026.
Cullgen (search) Inc., a clinical-stage biopharmaceutical company, announced the completion of enrollment in its Phase 1 clinical trial evaluating CG001419, a potential first-in-class oral pan-TRK (search) protein degrader for pain treatment. The milestone represents a significant step forward in developing non-addictive pain management alternatives.
Novel Mechanism Targets Pain Signaling
CG001419 operates through targeted protein degradation of tropomyosin receptor kinase (TRK (search)), representing a new class of pain signal inhibitors. Unlike traditional opioid therapies, this approach aims to eliminate the risk of addiction while providing effective pain relief for both acute and chronic conditions.
"We are excited about our progress with CG001419 because it is a potentially new, non-opioid, non-NSAID analgesic therapy that is part of a new class of pain signal inhibitors that have the potential to reduce the risk of addiction associated with other pharmaceutical therapies for the treatment of pain," said Ying Luo, Ph.D., Chief Executive Officer of Cullgen (search).
Phase 1 Trial Design and Progress
The Phase 1 trial (NCT06636500) received ethics committee approval in Australia earlier this year and enrolled healthy volunteers in a single-center study. The randomized, placebo-controlled, double-blind trial follows a single-ascending-dose/food-effect and multiple-ascending-dose design to evaluate the safety, tolerability and pharmacokinetic characteristics of CG001419.
The company's goal extends beyond current non-opioid options available to patients. "Our goal is to be able to offer patients suffering from acute and chronic pain a new treatment option that is safer and more effective than other non-opioids currently available," Luo explained.
Regulatory Timeline and Development Strategy
Cullgen (search) anticipates filing an Investigational New Drug (IND) application with the FDA to enable Phase 2 trials for CG001419 in pain management by early 2026. This timeline positions the company to advance its lead candidate into efficacy studies within the next year.
The development of CG001419 leverages Cullgen (search)'s expertise in targeted protein degrader therapies, which the company believes offer distinct advantages over other therapeutic modalities, including higher selectivity, improved therapeutic profiles and avoidance of known toxicities.
Broader Pipeline Applications
Beyond pain management, CG001419 is also being studied in a separate Phase 1 trial for solid tumor treatment, demonstrating the versatility of the pan-TRK (search) degrader approach. Cullgen (search)'s pipeline includes additional candidates such as CG009301, a GSPT1 (search) degrader in Phase 1 trials for blood cancers including relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and acute lymphoblastic leukemia.
The company continues advancing preclinical programs featuring novel E3 ligands and next-generation degrader-antibody conjugates for oncology and inflammatory diseases, building on its targeted protein degrader platform.